In a report released yesterday, Ryan Zimmerman from BTIG maintained a Buy rating on Integra Lifesciences (IART), with a price target of $70. The company’s shares closed yesterday at $63.22, close to its 52-week high of $66.41.
According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of 31.5% and a 67.6% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, OrthoPediatrics Corp, and Stryker Corporation.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Integra Lifesciences with a $69.50 average price target, representing a 9.9% upside. In a report released yesterday, Piper Jaffray also reiterated a Buy rating on the stock with a $69 price target.
See today’s analyst top recommended stocks >>
Integra Lifesciences’ market cap is currently $5.4B and has a P/E ratio of 54.04. The company has a Price to Book ratio of 3.87.
Based on the recent corporate insider activity of 61 insiders, corporate insider sentiment is negative on the stock. Most recently, in May 2019, Christian Schade, a Director at IART sold 15,658 shares for a total of $807,326.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical, and Orthopedics and Tissue Technologies segments.
